Lupus & antiphospholipid syndrome
Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?
Authors' conclusion
The methodologic heterogeneity across studies and the overall moderate score of the quality of the articles represent obstacles to the implementation of new biomarkers into clinical practice.
Study context
- Population
- Studies of adult patients with biopsy-proven lupus nephritis (LN), published 2012–2024, correlating biomarkers with histopathology93 articles
- Outcome
- Quality of LN biomarker studies correlating with histopathology
Methodological detailsquality assessment by a multidisciplinary expert panel using a standardized scoring system
- Quality assessment by a multidisciplinary expert panel using a standardized scoring system
Pooled result
As reported in the abstract
Articles selected, investigating >100 biomarkers
93
Articles weak or very weak (score <5, scale 2-9)
68%
Biomarkers with potential for clinical implementation (from adequate or robust articles): TGF-β1, pentraxin-3, (soluble) CD163, CD11b, IL-16
5
Original publication
Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand? Arthritis Rheumatol. Published 28 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →